Novo Nordisk seeks to market insulin products

Insulin degludec, insulin degludec/insulin aspart to treat Type 1, Type 2 diabetes

PRINCETON, N.J. — Novo Nordisk is seeking approval for two new insulin products, the company said Thursday.

Novo Nordisk announced that it had filed with the Food and Drug Administration for approval of insulin degludec and a co-formulation of insulin degludec and insulin aspart. The products are insulin analogs developed for the treatment of Type 1 and Type 2 diabetes.

"We are very excited about being able to file for the approval of insulin decludec and insulin deluded [with] insulin aspart now also in the U.S.," Novo Nordisk EVP and chief science officer Mads Krogsgaard Thomsen said. "This is another significant milestone for Novo Nordisk and for the millions of people with diabetes who require insulin."

Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

Login or Register to post a comment.